Rasburicase in tumor lysis syndrome of the adult: A systematic review and meta-analysis

American Journal of Kidney Diseases

Volumn 62, Issue 3, 2013, Pages 481-492

  Lopez Olivo, Maria A ^a   Pratt, Gregory ^a   Palla, Shana L ^a   Salahudeen, Abdulla ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

acute kidney injury; allopurinol; cost; hyperuricemia; leukemia; lymphoma; nonrecombinant urate oxidase; outcomes; rasburicase; Recombinant urate oxidase; tumor lysis syndrome (TLS)

Indexed keywords

ALLOPURINOL; CREATININE; RASBURICASE; URIC ACID;

ACUTE KIDNEY FAILURE; ARTICLE; CHEMOPROPHYLAXIS; DRUG FATALITY; HUMAN; HYPERURICEMIA; META ANALYSIS; OBSERVATIONAL STUDY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

ACUTE KIDNEY INJURY; ALLOPURINOL; COST; HYPERURICEMIA; LEUKEMIA; LYMPHOMA; NONRECOMBINANT URATE OXIDASE; OUTCOMES; RASBURICASE; RECOMBINANT URATE OXIDASE; TUMOR LYSIS SYNDROME (TLS);

ADULT; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 84883260224     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.02.378     Document Type: Article

References (44)

1. M.S. Cairo, B. Coiffier, A. Reiter, A. Younes Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus Br J Haematol 149 4 2010 578 586
2. E. Rampello, T. Fricia, M. Malaguarnera The management of tumor lysis syndrome Nat Clin Pract Oncol 3 8 2006 438 447
3. D.K. Cheuk, A.K. Chiang, G.C. Chan, S.Y. Ha Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer Cochrane Database Syst Rev 6 2010 CD006945
4. Drugs@FDA Highlights of prescribing information 2009 http:// wwwaccessdatafdagov/scripts/cder/drugsatfda/indexcfm?fuseaction= SearchLabel-ApprovalHistory#apphist Accessed December 2, 2011
5. J.E. Cortes, J.O. Moore, R.T. Maziarz Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - results of a multicenter phase III study J Clin Oncol 28 27 2010 4207 4213
6. A. Bosly, A. Pinkerton, C. Ross Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study Cancer 98 5 2003 1048 1054
7. V. Pitini, P. Bramanti, C. Arrigo, E. Sessa, G. La Gattuta, C. Amata Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient Ann Oncol 15 9 2004 1446
8. B. Coiffier, A. Altman, C.H. Pui, A. Younes, M.S. Cairo Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review J Clin Oncol 26 16 2008 2767 2778
9. A. Liberati, D.G. Altman, J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
10. J.P.T. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [updated March 2011] 2011 The Cochrane Collaboration www.cochrane-handbook.org Accessed February 11, 2013
11. D.F. Stroup, J.A. Berlin, S.C. Morton Meta-analysis of Observational Studies in Epidemiology: a proposal for reporting Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 283 15 2000 2008 2012
12. M.S. Cairo, M. Bishop Tumour lysis syndrome: new therapeutic strategies and classification Br J Haematol 127 1 2004 3 11
13. G.A. Wells, B. Shea, D. O'Connell The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 1999 Ottawa Health Research Institute Ottawa, Canada http://www.ohri.ca/programs/clinical- epidemiology/oxford.htm Accessed December 2, 2011
14. S.G. Thompson, J.P. Higgins How should meta-regression analyses be undertaken and interpreted? Stat Med 21 11 2002 1559 1573
15. D.J. Reeves, D.J. Bestul Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer Pharmacotherapy 28 6 2008 685 690
16. K. Ishizawa, M. Ogura, M. Hamaguchi Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study Cancer Sci 100 2 2009 357 362
17. S. Vadhan-Raj, L.E. Fayad, M.A. Fanale A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome Ann Oncol 23 6 2012 1640 1645
18. S. Vadhan-Raj, K. Ames, S. Oroark, X. Zhou, N. Sarlis, C. Bueso-Ramos Efficacy and biologic effects of rasburicase (RSB) administered as a single dose followed by as needed dosing vs. standard fixed five days dosing in adult patients with hematologic malignancies at risk for tumor lysis syndrome: randomized clinical trial Support Care Cancer 18 2010 S220
19. S. Vadhan-Raj, L. Fayad, M. Fanale Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome Blood 114 22 2009 48 49
20. B. Coiffier, N. Mounier, S. Bologna Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study J Clin Oncol 21 23 2003 4402 4406
21. S. Jeha, C.-H. Pui Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome Contrib Nephrol 147 2005 69 79
22. S. Jeha, H. Kantarjian, D. Irwin Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial Leukemia 19 1 2005 34 38
23. F. Lascombes, D. Sommelet, F. Gebhard High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS) Blood 92 10 1998 237B
24. D. Pohlreich, P. Soukup, M. Kouba Reduced-dose regimen of rasburicase with parallel allopurinol in the management of malignancy-associated hyperuricemia and tumor lysis syndrome Bone Marrow Transplant 31 2003 S223 S224
25. C.H. Pui Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience Semin Hematol 38 4 2001 13 21 (suppl 10)
26. C.H. Pui, S. Jeha, D. Irwin, B. Camitta Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial Leukemia 15 10 2001 1505 1509
27. L.-Y. Wang, L.-Y. Shih, H. Chang Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies Acta Haematol 115 1-2 2006 35 38
28. A. McDonnell, P.D. Hall, K. Lenz, R. Hayslip, D. Frei-Lahr A single 6 milligram dose of rasburicase for the management of tumor lysis syndrome in adults Pharmacotherapy 25 10 2005 1485
29. A.M. McDonnell, K.L. Lenz, D.A. Frei-Lahr, J. Hayslip, P.D. Hall Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults Pharmacotherapy 26 6 2006 806 812
30. V.Q. Ho, G.A. Wetzstein, S.G. Patterson, R. Bradbury Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome Support Cancer Ther 3 3 2006 178 182
31. D.A. Hutcherson, D.C. Gammon, M.S. Bhatt, M. Faneuf Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy Pharmacotherapy 26 2 2006 242 247
32. F. Llinares, A. Burgos, P. Fernandez, B. Villarrubia, P. Ferrandis, J.P. Ordovas [Analysis and protocolization of rasburicase use in patients with hematologic neoplasms] Farm Hosp 30 2 2006 92 98
33. S. Steel, J. Coutsouvelis, J. McKendrick Single dose rasburicase in tumor lysis: one hospital's experience Asia Pac J Clin Oncol 4 1 2008 18 20
34. V.F. Chow, K.J. Lee Single fixed dose versus weight-based dosing of rasburicase for the treatment of hyperuricemia associated with tumor lysis syndrome in adults with hematologic malignancies J Supportive Oncol 7 5 2009 196 197
35. M. Campara, S.S. Shord, C.M. Haaf Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach J Clin Pharm Ther 34 2 2009 207 213
36. R.W. Knoebel, M. Lo, C.W. Crank Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome J Oncol Pharm Pract 17 3 2011 147 154
37. A.N. Vines, C.B. Shanholtz, J.L. Thompson Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients Ann Pharmacother 44 10 2010 1529 1537
38. B. Yim, A. Navaleza, A. Haidau Single 4.5mg dose of rasburicase for tumor lysis syndrome in adults Blood 116 21 2010 741 742
39. S.M. Trifilio, J. Pi, J. Zook Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies Bone Marrow Transplant 46 6 2011 800 805
40. S. Trifilio, L. Gordon, S. Singhal Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia Bone Marrow Transplant 37 11 2006 997 1001
41. F.W.T. Cheng, J. Xiao, C.K. Li Management of tumour lysis syndrome in non-Hodgkin lymphoma HK J Paediatr 14 2009 11 15
42. M. Bhandari, J.W. Busse, D. Jackowski Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials CMAJ 170 4 2004 477 480
43. L. Annemans, K. Moeremans, M. Lamotte Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients Support Care Cancer 11 4 2003 249 257
44. S.D. Grosse Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold Expert Rev Pharmacoecon Outcomes Res 8 2 2008 165 178